Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

46.99
-13.5550-22.39%
Pre-market: 47.460.4700+1.00%04:04 EDT
Volume:6.27M
Turnover:308.15M
Market Cap:1.60B
PE:-7.26
High:56.69
Open:55.41
Low:46.29
Close:60.55
52wk High:109.00
52wk Low:33.40
Shares:34.14M
Float Shares:28.53M
Volume Ratio:3.19
T/O Rate:21.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:1.78
PE(LYR):-4.83

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO

Reuters
·
Apr 20

Wedbush Lifts Price Target on Nektar Therapeutics to $95 From $70, Maintains Neutral Rating

MT Newswires Live
·
Apr 20

Nektar rises 19.4%

TIPRANKS
·
Apr 20

Nektar Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Apr 20

Nektar Therapeutics : Btig Raises Target Price to $178 From $151

THOMSON REUTERS
·
Apr 20

Nektar Therapeutics : H.c. Wainwright Raises Target Price to $185 From $165

THOMSON REUTERS
·
Apr 20

Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday

Benzinga_recent_news
·
Apr 20

Nektar Therapeutics Says New Rezpegaldesleukin Data Shows 'Deepening of Response' in Alopecia

MT Newswires Live
·
Apr 20

BUZZ-U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen

Reuters
·
Apr 20

Nektar Therapeutics Shares up 17.8% Premarket After Alopecia Treatment Shows Promise in Extension Study

THOMSON REUTERS
·
Apr 20

Nektar Says In-Development Treatment for Hair Loss Has Promise

Dow Jones
·
Apr 20

Nektar reports new results from Phase 2b REZOLVE-AA study

TIPRANKS
·
Apr 20

Nektar Therapeutics - 29% and 31% of Patients Achieve Salt Score ≤20 From Week 36 to Week 52

THOMSON REUTERS
·
Apr 20

Nektar Therapeutics - Rezpegaldesleukin to Advance Into Late-Stage Development for Alopecia Areata

THOMSON REUTERS
·
Apr 20

52-Week Topline Results From 16-Week Blinded Treatment Extension of Rezolve-Aa Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata With Rezpegaldesleukin

THOMSON REUTERS
·
Apr 20

Nektar Therapeutics - Favorable Safety Profile Maintained Throughout 52 Weeks

THOMSON REUTERS
·
Apr 20

Nektar Therapeutics - 94% of Patients Completed Treatment Extension With Clinically Meaningful Hair Growth

THOMSON REUTERS
·
Apr 20

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM

Reuters
·
Apr 20

Why Nektar Therapeutics (NKTR) Is Up 5.5% After 52-Week REZOLVE-AA Rezpegaldesleukin Data Release And What's Next

Simply Wall St.
·
Apr 20

Nektar to present 52-week REZOLVE-AA Phase 2b rezpegaldesleukin topline results April 20

Reuters
·
Apr 20